Schering AG Making Oncology A Primary Focus; Dermatology Unit Will Become Separate Entity
This article was originally published in The Pink Sheet Daily
Executive Summary
Berlex’ German parent says the new focus will help it exploit the potential of a Phase III angiogenesis inhibitor under development with Novartis. Portfolio restructuring includes termination of R&D in cardiovascular and CNS areas, except for multiple sclerosis and Parkinson’s disease.
You may also be interested in...
Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit
Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.
Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit
Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.
Novartis/Schering AG's Vatalanib Efficacy Not CONFIRMed; Filing Delayed Until 2007
Colorectal cancer agent fails to meet primary endpoint of central radiology review-assessed progression-free survival in the CONFIRM-1 trial, Novartis says. The company expects data on overall survival for the agent, also known as PTK-ZK, to be available in the second half of 2006.